In 2000, a father's determination to free his son from the daily burden of multiple insulin injections sparked the creation of Insulet. That deeply personal mission led to a revolutionary idea sketched on a napkin: a tubeless, wearable insulin delivery system. Over the past two decades, that vision has evolved into Omnipod technology that now serves over 600,000 customers across 25 countries. The company has grown from a compassionate idea into a publicly traded innovator (NASDAQ: PODD) with $2.1 billion in revenue, proving that purpose-driven innovation can transform both lives and industries.
Today, Insulet stands at the forefront of diabetes management technology, having launched the world's first tubeless automated insulin delivery system controlled by a smartphone. The company's relentless passion extends beyond product development - they advocate tirelessly for their community of "Podders," push for sustainable and responsible growth, and maintain operations spanning North America, Europe, the Middle East, and Asia Pacific. With the Omnipod 5 system now the #1 prescribed automated insulin delivery system in the U.S., Insulet continues to innovate toward their mission of making diabetes a smaller part of life through technology that offers unprecedented simplicity, freedom, and healthier outcomes.
